Recurrent CNVs disrupt three candidate genes in schizophrenia patients by Vrijenhoek Terry, Buizer-Voskamp Jacobine E, van der Stelt Inge, Strengman Eric, Genetic Risk and Outcome in Psychosis (GROUP) Consortium, Sabatti Chiara, Geurts van Kessel Ad, Brunner Han G, Ophoff Roel A, Veltman Joris A in American journal of human genetics (2008).

[PMID: 18940311] PubMed


Schizophrenia is a severe psychiatric disease with complex etiology, affecting approximately 1% of the general population. Most genetics studies so far have focused on disease association with common genetic variation, such as single-nucleotide polymorphisms (SNPs), but it has recently become apparent that large-scale genomic copy-number variants (CNVs) are involved in disease development as well. To assess the role of rare CNVs in schizophrenia, we screened 54 patients with deficit schizophrenia using Affymetrix's GeneChip 250K SNP arrays. We identified 90 CNVs in total, 77 of which have been reported previously in unaffected control cohorts. Among the genes disrupted by the remaining rare CNVs are MYT1L, CTNND2, NRXN1, and ASTN2, genes that play an important role in neuronal functioning but--except for NRXN1--have not been associated with schizophrenia before. We studied the occurrence of CNVs at these four loci in an additional cohort of 752 patients and 706 normal controls from The Netherlands. We identified eight additional CNVs, of which the four that affect coding sequences were found only in the patient cohort. Our study supports a role for rare CNVs in schizophrenia susceptibility and identifies at least three candidate genes for this complex disorder.

[ hide abstract ]

Discussed In Paper


Rx Annotations

No dosing information annotated.